

Press release
For immediate release

VICTHOM TO LIST ON TSX VENTURE EXCHANGE AND VOLUNTARILY DELIST FROM TORONTO STOCK EXCHANGE

Quebec (Canada), December 30, 2009 - Victhom Human Bionics Inc. ("Victhom" or the "Company", TSX: VHB) announced today that concurrent to voluntary delisting from the Toronto Stock Exchange, the common shares of the Company will commence trading on the TSX Venture Exchange effective at the opening of trading on December 31, 2009. The Company will be classified as a Tier 1 Technology Issuer on the TSX Venture Exchange. The Company's common shares trading symbol, "VHB", and their CUSIP number, 92581Q502, will remain unchanged.

It is Victhom's view that a listing on the TSX Venture Exchange is appropriate given the current nature of the Company's activities and is consistent with the ongoing process of cost rationalization.

About Victhom

Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's wholly owned subsidiary, Victhom Bionized Inc., develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market. Victhom also has a 44.4% interest in Neurostream Technologies, General Partnership, a joint venture with Otto Bock HealthCare GmbH, which focuses on the development and commercialization of technologies and products involving devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence.

FORWARD-LOOKING STATEMENTS

Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.



Victhom Human Bionics

Source: Victhom Human Bionics Inc.

For more information about Victhom:

Normand Rivard
President & CEO
Victhom Human Bionics Inc.
Tel.: 418-872-5665
Fax: 418-872-6926
normand.rivard@victhom.com
www.victhom.com